



## Covishield and Covaxin Immunogenicity

[Source: TH](#)


A recent study led by scientists from the **National Centre for Biological Sciences (NCBS)** and conducted across 11 institutes has provided compelling insights into the **immunogenicity** of 2 primary **Covid-19 vaccines** in India: [Covishield and Covaxin](#).

- **Immunogenicity** refers to the **ability of a substance**, such as a vaccine or antigen, **to provoke an immune response in the body**.
  - This response typically involves the production of antibodies and activation of immune cells, leading to protection against infection or disease.
- The recent study examined the immune responses induced by Covishield and Covaxin vaccines against **SARS-CoV-2**.
  - **Covishield, utilising a virus vector** to deliver the coronavirus spike protein, consistently elicited a **more robust immune response** (higher antibody levels in both **seronegative (individuals without prior exposure)** and **seropositive (individuals with prior exposure)**) **compared to Covaxin**, an inactivated virus vaccine.
  - Additionally, Covishield elicited a **greater number of T cells**, indicating a stronger immune response.

//



# How do different Covid-19 vaccines work?



Read more: [Covishield and Covaxin](#)

PDF Reference URL: <https://www.drishtias.com/printpdf/covishield-and-covaxin-immunogenicity>